About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
Statement of Purpose
Guidelines for Authors
Health Care Reform
The Next Critical Step: Educating Consumers and Small Businesses
By the end of 2012, states must figure out how they will provide exchanges for citizens to buy health care insurance. Much work remains to be done, including removing information barriers, to make health care accessible to all citizens by 2014.
Challenges and Solutions for Physicians and Patients
Four recently approved drugs (cabazitaxel, sipuleucel-T, abiraterone, and denosumab), along with emerging therapies, bone-building therapies, hormonal treatments, and immunotherapies, have all demonstrated promise in advanced prostate cancer. It appears that the best outcomes will be achieved from the sequential use of multiple agents.
Carole Alison Chrvala, PhD
Clinical and Economic Outcomes
Men with benign prostatic hyperplasia who received 5-ARIs and persisted with therapy had significantly reduced risks of acute urinary retention, less need for prostate surgery, and lower medical costs.
Stephen Gruschkus, PhD, MPH; Sara Poston, PharmD; Michael Eaddy, PharmD, PhD; and Sham Chaudhari, MS, PharmB
2012 American Society of Clinical Oncology and American Society of Hypertension (27th Annual Scientific Meeting and Exposition)
Selected ASCO topics include drugs for melanoma, gastrointestinal tumors, non–small cell lung cancer, and advanced breast cancer. ASH presentations cover ambulatory blood pressure in type-2 diabetes, triple therapy in obese patients, the effect of body mass on cardiovascular outcomes, and a novel glucagon-like peptide agonist for diabetes.
Mixups of epidural and intravenous drugs can be deadly.
Matthew Grissinger, RPh, FASCP
Act Omits Key Provisions Sought by Pharmacy Groups
The FDA’s PDUFA reauthorization bill passes but omits significant safety provisions.
FDA approvals, drug indications, and updates
A Novel Agent for Metastatic Castration-Resistant Prostate Cancer
Cabazitaxel (Jevtana) for metastatic castration-resistant prostate cancer
Ginah Nightingale, PharmD, BCOP; and Jae Ryu, PharmD, BCOP, BCPS